Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company developing immunotherapy-based cancer treatments. The company is focused on advancing proprietary drug candidates designed to stimulate anti-tumor immune responses, rather than selling commercial products today.

1.51

1.51

— Indaptus Therapeutics, Inc.
%
Oncology immunotherapy candidates100% Experimental drug candidates intended to treat cancer by activating the immune system.
Platform-based drug discovery0% Underlying technology and research platform used to generate and optimize therapeutic candidates.
Clinical development services0% Internal development activities supporting trials, regulatory work, and translational studies.

Indaptus does not appear to have a commercial customer base yet; its primary stakeholders are clinical investigators,...

  • Clinical trial ecosystemprimary

    Hospitals, investigators, and research sites that enroll patients and generate clinical data for the company's programs.

  • Regulatory authoritiesprimary

    FDA and other agencies that review trial protocols, safety data, and eventual approval packages.

  • Future oncology providersemerging

    Oncologists, hospitals, and cancer centers that could prescribe or administer an approved therapy.

  • Future payersemerging

    Insurers and health systems that would evaluate reimbursement only if a product reaches market.

The company is based in the United States and its operations are centered on U.S.-based corporate, research, and...

  • •Headquartered in the United States
  • •Clinical and regulatory activity is primarily U.S.-focused
  • •No disclosed commercial revenue by country
  • •Geography matters more for trial execution than sales

Indaptus' strategy is to advance its immunotherapy pipeline through clinical proof-of-concept and de-risk the platform...

01
Advance clinical developmentshort-term

Human data are the main value driver for a pre-commercial biotech.

02
Validate the platformmedium-term

Platform credibility can support multiple programs and partnering interest.

03
Secure funding and optionalityshort-term

Development-stage biotech typically requires external capital before commercialization.

The company faces the classic risks of a clinical-stage biotech: trial failure, safety setbacks, and difficulty raising...

critical

Clinical development failure

The company depends on a limited pipeline, so negative efficacy data can materially impair value.

Scope
Lead oncology programs
Materiality
high
high

Safety/tolerability setbacks

Immunotherapy candidates can trigger adverse events that limit dose, enrollment, or approval prospects.

Scope
Human trials
Materiality
high
high

Financing and dilution risk

As a pre-revenue company, operations likely depend on periodic equity or partnership funding.

Scope
Cash runway and trial funding
Materiality
high
medium

Regulatory and trial execution risk

Enrollment delays, protocol changes, or agency feedback can slow development and increase costs.

Scope
Clinical operations
Materiality
medium
Research and development expense recognition
Affects operating loss and comparability across periods
Stock-based compensation
Can materially increase reported operating expenses
Fair value of warrants/derivatives
Can add volatility unrelated to core development progress
Going-concern assessment
Important for liquidity and solvency analysis

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

BriaCell Therapeutics Corp.

BCTX · Pharmaceutical Preparations

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

: 28/04/2026